You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • FRI0097 Comparative effectiveness and time to response among adalimumab, abatacept, etanercept, infliximab and rituximab in a real world routine care registry

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Poster Presentations
Posters
Rheumatoid arthritis – prognosis, predictors and outcome
FRI0097 Comparative effectiveness and time to response among adalimumab, abatacept, etanercept, infliximab and rituximab in a real world routine care registry

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Yazici Y, Regens A, Swearingen C
FRI0097 Comparative effectiveness and time to response among adalimumab, abatacept, etanercept, infliximab and rituximab in a real world routine care registry
Annals of the Rheumatic Diseases 2013;71:342.